Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation

Bone Marrow Transplantation

Volumn 42, Issue 2, 2008, Pages 113-120

  Haentzschel, I ^a   Freiberg Richter, J ^a   Platzbecker, U ^a   Kiani, A ^a   Schetelig, J ^a   Illmer, T ^a   Ehninger, G ^a   Schleyer, E ^b   Bornhauser M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Carl von Basedow Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; BUSULFAN; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; INFLIXIMAB; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISOLONE; STEROID; TACROLIMUS;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TARGETING; FEMALE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCIDENCE; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL;

ADULT; AGED; AREA UNDER CURVE; DRUG MONITORING; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TRANSPLANTATION, HOMOLOGOUS;

EID: 48349083068     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.85     Document Type: Article

References (34)

1. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant 1999; 5: 347-356.
2. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D et al Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61-65.
3. Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499-504.
4. Dvorak CC, Callard E, Agarwal R. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus. Bone Marrow Transplant 2006; 38 253-254.
5. Mohty M, de Lavallade H, Faucher C, Bilger K, Vey N, Stoppa AM et al Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 527-530.
6. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
7. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT et al A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 495-505.
8. Jenke A, Renner U, Richte M, Freiberg-Richter J, Platzbecker U, Helwig A et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 2001; 15: 176-184.
9. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 36: 315-324.
10. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-455.
11. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820-826.
12. Jenke A, Freiberg-Richter J, Johne C, Knoth H, Schleyer E, Ehninger G et al. Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005; 35: 627-628.
13. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: A prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003; 43: 866-880.
14. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Korbling M et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 763-768.
15. Renner UD, Thiede C, Bornhauser M, Ehninger G, Thiede HM. Determination of mycophenolic acid and mycophenolate mofetil by high-performance liquid chromatography using postcolumn derivatization. Anal Chem 2001; 73: 41-46.
16. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998; 31: 317-322.
17. Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C et al Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055-1060.
18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
19. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997; 16: 901-910.
20. Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006; 37: 1143-1147.
21. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24: 517-520.
22. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
23. Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998; 91: 2581-2587.
24. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35: 1089-1093.
25. Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: Preliminary findings. Bone Marrow Transplant 2001; 27: 1255-1262.
26. Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005; 106: 4381-4388.
27. Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D et al Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005; 78: 486-500.
28. van Hest RM, Doorduijn JK, de Winter BC, Cornelissen JJ, Vulto AG, Oellerich M et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 2007; 29: 353-360.
29. Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB et al Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006; 12: 217-225.
30. Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004; 10: 246-258.
31. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145-154.
32. McPhillips CC, Hyle JW, Reines D. Detection of the mycophenolate-inhibited form of IMP dehydrogenase in vivo. Proc Natl Acad Sci USA 2004; 101: 12171-12176.
33. Storck M, Abendroth D, Albrecht W, Sollinger HW. IMPDH activity in whole blood and isolated blood cell fraction for monitoring of CellCept-mediated immunosuppression. Transplant Proc 1999; 31 1115-1116.
34. Arns W, Gies M, Choi L, Zhu W, Cooper P, Yeh CM et al. Absorption characteristics of EC-MPS-an enteric-coated formulation of mycophenolic sodium. Int J Clin Pharmacol Ther 2006; 44: 375-385.